

HOGAN & HARTSON

L.L.P.

3178 '04 FEB 25 2413

DAVID M. FOX
PARTNER
(202) 637-5678
DMFOX@HHLAW.COM

COLUMBIA SQUARE
555 THIRTEENTH STREET, NW
WASHINGTON, DC 20004-1109
TEL (202) 637-5600
FAX (202) 637-5910
WWW.HHLAW.COM

February 25, 2004

BY HAND DELIVERY

Dockets Management Branch
Food and Drug Administration
Department of Health and Human Services
5630 Fishers Lane, Room 1061
Rockville, MD 20852

***Re: Citizen Petition, Intent to Respond to Teva Comments
Docket No. 2003P-0321/CP1***

Dear Sir or Madam:

On February 23, 2004, we obtained from the Food and Drug Administration's Division of Dockets Management a copy of comments recently submitted by Teva Pharmaceuticals USA, Inc. in opposition to the above-referenced citizen petition.

By this letter, we are providing notice to the Food and Drug Administration of our intent to respond on behalf of the petitioner, Valeant Pharmaceuticals International (formerly known as ICN Pharmaceuticals, Inc. and Ribapharm Inc.), to Teva's opposing arguments. We intend to respond within thirty days of the date we received the comments.

As always, we thank you for your attention and your courtesy in this matter.

Sincerely,



David M. Fox

2003P-0321

LET 4

BERLIN BRUSSELS LONDON PARIS BUDAPEST PRAGUE WARSAW MOSCOW TOKYO

\\DC - 86689/0013 - 1887 NEW YORK BALTIMORE MCLEAN MIAMI DENVER BOULDER COLORADO SPRINGS LOS ANGELES